Showing 2681 results for "amyotrophic lateral sclerosis (ALS)"

FDA Names Ibudilast an Orphan Drug as Possible ALS Treatment

The U.S. Food and Drug Administration (FDA) has designated  MediciNova’s Ibudilast (MN-166) an orphan drug as a potential treatment for amyotrophic lateral sclerosis (ALS). Ibudilast is a first-in-class, orally bioavailable small molecule phosphodiesterase (PDE)-4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors.

Pastor Battles ALS but Still Inspires Others

In this Houston Methodist video, we get to meet Kevin Kinchen. Kevin was diagnosed with amyotrophic lateral sclerosis (ALS) six years ago, but he hasn’t let that stop him from getting on with his life.  Nanci is a much-loved Hollywood publicist who was diagnosed with amyotrophic lateral sclerosis (ALS)…

What Is the Penn’s Comprehensive ALS Center?

Patients with amyotrophic lateral sclerosis (ALS) experience a gradual loss of the ability to walk, swallow and even breathe, and there’s no cure. It’s incredibly important that patients seek specialized treatment to address the different aspects of the disease. Find out seven ways to diagnose ALS. In this…

New Preclinical Data of Masitinib for ALS Presented at 4 Scientific Meetings This Year

AB Science has been invited to present new preclinical studies on masitinib in the treatment of amyotrophic lateral sclerosis (ALS) at four international meetings this year. These were the main findings from the series of preclinical studies: Proof of concept data from the preclinical trials of masitinib showed that the investigational drug “targets…

Living with ALS: Nanci Ryder’s Story

Find out more about the story of Nanci Ryder in this ALS Association video. Nanci is a much-loved Hollywood publicist who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2014. Read about the four ALS heroes the ALS Association chose to honor for outstanding contributions.  The ALS Association’s…

ALS End-stage Brain Damage Isn’t Limited to Motor Neurons, Study Finds

Patients with amyotrophic lateral sclerosis (ALS) who have progressed to a stage in which they’ve lost all voluntary movements, including the ability to communicate, have damage in numerous brain regions and isn’t limited to motor neurons. The study, “Clinicopathological characteristics of patients with amyotrophic lateral sclerosis resulting in…